---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-148107"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:29:19.855329+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine CEO Kevin Gorman to retire Oct 11; Kyle Gano appointed successor

## Summary
- Kevin C. Gorman, Ph.D. to retire as President and CEO effective October 11, 2024; will remain on the board.
- Kyle Gano, Ph.D., current Chief Business Development and Strategy Officer, becomes President and CEO on same date.
- Gano appointed to the board as a Class II director effective October 11, 2024.
- Board size increased from 10 to 11 via bylaw amendment to accommodate Gano's appointment.

## SEC filing metadata
- accession: 0001193125-24-148107
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/d836271d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-148107
- JSON: https://secwatch.observer/filing/0001193125-24-148107.json
- Plain text: https://secwatch.observer/filing/0001193125-24-148107.txt

## Key facts
- Executive change
  Kevin C. Gorman retired as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.
  - Action: retired
  - Role: President and Chief Executive Officer
  source text: Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm
- Executive change
  Kyle Gano was appointed as Class II Director at NEUROCRINE BIOSCIENCES INC.
  - Action: appointed
  - Role: Class II Director
  source text: effective as of the Transition Date, Dr. Gano has been appointed to the Board as a Class II director to serve until Neurocrine’s 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm
- Executive change
  Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.